WT1 and plasma cell myeloma: WT-1 specific T cells generated from normal HSCT donors were administered at escalating doses (3.8 × 108 to 3.3 × 109/m2) to 11 patients with WT-1+ leukaemia, MDS, or myeloma in disease relapse post-transplantation [58].